Literature DB >> 18292496

Cutting edge: selective expression of inhibitory or activating killer cell Ig-like receptors in circulating CD4+ T lymphocytes.

Natacha Remtoula1, Armand Bensussan, Anne Marie-Cardine.   

Abstract

Apart from NK cells, TCRgammadelta and CD8+ T cells, killer cell Ig-like receptor (KIR) expression was described on a minor subset of CD4+ T cells. However, their functions remain to be elucidated in this latter lymphocyte population. We demonstrated that KIR2DL2/L3 (CD158b) and KIR2DS2 (CD158j) transcripts were synthesized by sorted CD4+CD158b/j+ T cells obtained from healthy individuals. In contrast, we observed that only the inhibitory or activating receptor was expressed at the cell surface according to the donor tested. In CD158b-expressing cells, KIR triggering leads to an inhibition of the CD3-induced cell proliferation and Erk activation, and the receptor exhibits an activation-dependent tyrosine phosphorylation and association with the Src homology 2-containing phosphatase 1. In CD158j-positive cells, KIR-engagement results in an enhanced CD3-mediated cell growth and Erk phosphorylation. Our results suggested that, in contrast to NK cells, the functions of KIR in CD4+ T lymphocytes might derive from a selective expression of their activating or inhibiting forms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292496     DOI: 10.4049/jimmunol.180.5.2767

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Contribution of functional KIR3DL1 to ankylosing spondylitis.

Authors:  Ivan V Zvyagin; Ilgar Z Mamedov; Olga V Britanova; Dmitriy B Staroverov; Evgeni L Nasonov; Anna G Bochkova; Anna V Chkalina; Alexei A Kotlobay; Dmitriy O Korostin; Denis V Rebrikov; Sergey Lukyanov; Yuri B Lebedev; Dmitriy M Chudakov
Journal:  Cell Mol Immunol       Date:  2010-09-06       Impact factor: 11.530

2.  Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.

Authors:  Enxiu Wang; Liang-Chuan Wang; Ching-Yi Tsai; Vijay Bhoj; Zack Gershenson; Edmund Moon; Kheng Newick; Jing Sun; Albert Lo; Timothy Baradet; Michael D Feldman; David Barrett; Ellen Puré; Steven Albelda; Michael C Milone
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

3.  KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis.

Authors:  José A Campillo; Isabel Legaz; M Rocío López-Álvarez; José Miguel Bolarín; Beatriz Las Heras; Manuel Muro; Alfredo Minguela; María R Moya-Quiles; Rosa Blanco-García; Helios Martínez-Banaclocha; Ana M García-Alonso; M Rocío Alvarez-López; Jorge A Martínez-Escribano
Journal:  Immunogenetics       Date:  2013-01-31       Impact factor: 2.846

4.  Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies.

Authors:  Gaëlle David; Maelig Morvan; Katia Gagne; Nolwenn Kerdudou; Catherine Willem; Anne Devys; Marc Bonneville; Gilles Folléa; Jean-Denis Bignon; Christelle Retière
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

Review 5.  Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology.

Authors:  Vivien Béziat; Hugo G Hilton; Paul J Norman; James A Traherne
Journal:  Immunology       Date:  2016-12-14       Impact factor: 7.397

6.  Genotype B of Killer Cell Immunoglobulin-Like Receptor is Related with Gastric Cancer Lesions.

Authors:  Eric G Hernandez; Oswaldo Partida-Rodriguez; Margarita Camorlinga-Ponce; Miriam Nieves-Ramirez; Irma Ramos-Vega; Javier Torres; Martha Perez-Rodriguez
Journal:  Sci Rep       Date:  2018-04-17       Impact factor: 4.379

Review 7.  Progress in our understanding of the pathogenesis of ankylosing spondylitis.

Authors:  Davide Simone; M Hussein Al Mossawi; Paul Bowness
Journal:  Rheumatology (Oxford)       Date:  2018-08-01       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.